Table 4.
Functional effect (% stimulation and % inhibition) and efficacy (EC50 and IC50) of isoliquiritigenin on human dopamine (D1 and D3) and vasopressin(V1A) receptors.
| Receptors | % Stimulationa (% Inhibition)b | EC50c (IC50)d | Reference agoniste (reference antagonist)f | Reference EC50g (IC50)h |
|---|---|---|---|---|
| D1 | − 0.5 ± 2.1 (91.9 ± 3.1) | 68.9 ± 0.2 | Dopamine (SCH23390) | 44 (1.3) |
| D3 | 92.7 ± 0.5 (− 6.5 ± 5.2) | 62.3 ± 0.2 | Dopamine (( +)Butaclamol) | 2.9 (17) |
| V1a | 73.3 ± 4.0 (104.6 ± 1.8) AGO | 78.6 ± 2.7 | Vasopressin ([d(CH2)51, Tyr(Me)2]-AVP) | 0.46 (2.3) |
a,bThe % stimulation and the % inhibition denote the percentage of control agonist response and the percentage inhibition of the control agonist response by isoliquiritigenin at 100 µM.
cThe concentration producing a half maximal response (µM).
dThe concentration producing half maximal inhibition of the control agonist response (µM).
e,fReference agonists and reference antagonists used in the assay.
gThe EC50 value of the reference agonist (nM).
hThe IC50 value reference antagonist (nM). AGO: The test compound induced at least 25% agonist or agonist-like effects at this concentration.